CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction CellProthera, and BioCardia [Nasdaq: BCDA], today announce success from a collaborative Phase II trial of ProtheraCytes for the treatment of AMI.